Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

which targets CD20 and CD3 receptors on cells, and combination therapies. The deal is back-ended with $1.18 billion in potential milestones, plus royalties, and also covers a series of bispecifics ...

The trial showed that the double-headed antibody – which targets CD3 on white blood cells and CD20 on tumour cells – was tolerable and showed evidence of clinical activity in diffuse large B ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Medical treatment is initially based upon the use of corticosteroids to treat the inflammatory process. Ordinarily, this is given in the form of high-dose prednisone or equivalent steroids ...